on B.R.A.I.N. Biotechnology Research And Information Network AG (isin : DE0005203947)
BRAIN Biotech AG Reports Double-Digit Growth in Q1 2024/25
BRAIN Biotech AG announced a strong start to fiscal year 2024/25, driven by an 11% organic growth in its BRAINBiocatalysts division. This growth is reflected in the company's quarterly revenue increase to €13.1 million, a 3% rise from the previous year. The core BRAINBiocatalysts segment is highlighted by sales climbing to €11.9 million.
CEO Adriaan Moelker asserts confidence in sustained growth and anticipates a stable adjusted EBITDA margin around 10% for the year. Despite a 40% dip in BRAINBioIncubator segment revenues, attributed to project delays, the company maintains a strong cash position of €17.8 million and continues reducing financial debt.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all B.R.A.I.N. Biotechnology Research And Information Network AG news